Literature DB >> 3117135

Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma.

J Berenson1, R Wong, K Kim, N Brown, A Lichtenstein.   

Abstract

Because there is controversy regarding whether subsets of peripheral blood lymphocytes (PBLs) are part of the malignant clone in patients with multiple myeloma, we studied this question by immunoglobulin and T cell receptor gene analysis. Southern blot analysis with antibody probes demonstrated clonal immunoglobulin gene rearrangements in PBLs of seven of nine patients that were identical to those seen in their marrow plasma cells. Circulating plasma cells were not detected in any of these patients. In contrast, no patient demonstrated clonally rearranged T cell receptor genes. In one sequentially studied patient, PBLs obtained at diagnosis when he had stage I (Durie-Salmon) contained only germline DNA, while analysis of PBLs at relapse (stage III) revealed a clonally rearranged band. These data confirm the notion that circulating lymphocytes in patients with myeloma are part of the malignant clone and, furthermore, these malignant cells are of B cell rather than T cell lineage.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117135

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Establishment of a novel B cell clonality analysis using single-strand conformation polymorphism of immunoglobulin light chain messenger signals.

Authors:  S Shiokawa; J Nishimura; K Ohshima; N Uike; K Yamamoto
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

2.  Phenotype and immunoglobulin gene configuration of blood B cells from patients with multiple myeloma.

Authors:  Y Levy; C Schmitt; A Tsapis; J C Brouet; J P Fermand
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

Review 3.  Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention?

Authors:  Q Yi; A Osterborg
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

4.  Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selection.

Authors:  R G Owen; A P Haynes; P A Evans; R J Johnson; A C Rawstron; G McQuaker; G M Smith; M C Galvin; D L Barnard; N H Russell; J A Child; G J Morgan
Journal:  Clin Mol Pathol       Date:  1996-04

5.  Generation of T cell clones binding F(ab')2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy.

Authors:  A Osterborg; M Masucci; S Bergenbrant; G Holm; A K Lefvert; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 6.  Homing behaviour of the malignant cell clone in multiple myeloma.

Authors:  I Van Riet; K Vanderkerken; C de Greef; B Van Camp
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

7.  Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma.

Authors:  L Bergui; M Schena; G Gaidano; M Riva; F Caligaris-Cappio
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

8.  Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas.

Authors:  P Corradini; M Boccadoro; C Voena; A Pileri
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

9.  The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell.

Authors:  D Billadeau; G Ahmann; P Greipp; B Van Ness
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

10.  MM-BMSCs induce naïve CD4+ T lymphocytes dysfunction through fibroblast activation protein α.

Authors:  Xiaofei Wu; Yadan Wang; Jian Xu; Ting Luo; Jun Deng; Yu Hu
Journal:  Oncotarget       Date:  2017-04-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.